Physiomics Regulatory News (PYC)

Physiomics plc

("Physiomics") or ("the Company")

Physiomics launches new DrugCARD® database for oncology researchers and clinicians

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has now launched its Drug Combinations and Regimens database. DrugCARD® collates curated publicly available pre-clinical and clinical drug regimen data into one easily searchable tool. It also contains further clinical data and analysis which is only available through the collaboration with Pharmacometrics.

DrugCARD® currently contains clinical data for over 160 drugs used in over 700 regimens. Standards of care, novel targeted small molecule agents and biologics are all represented.

Using DrugCARD®, researchers, who will access the database on a subscription basis, will be able to rapidly compare regimen data and outcomes across a number of studies, saving them time and effort when literature-hunting. The Pharmacometrics data also adds pre-clinical and clinical modelling information not available elsewhere.

DrugCARD® can be accessed at: www.drug-card.co.uk

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to release the DrugCARD® database. This new product will allow us to rapidly access a wide range of target customers, including clinicians who have not previously been engaged and who would also benefit from using our emerging Virtual Tumour Clinical platform."

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® and DrugCARD® are registered trademarks of Physiomics plc

1Tufts Centre Impact Report 2002